Comparison of phenobarbital with bromide as a first-choice antiepileptic drug for treatment of epilepsy in dogs

Journal of the American Veterinary Medical Association

Volumn 240, Issue 9, 2012, Pages 1073-1083

  Boothe, Dawn Merton ^a   Dewey, Curtis ^b   Carpenter, David Mark ^a  

^a AUBURN UNIVERSITY   (United States)

^b Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BROMIDE; PHENOBARBITAL;

ANIMAL; ANIMAL DISEASE; ARTICLE; COMPARATIVE STUDY; DOG; DOG DISEASE; EPILEPSY; FEMALE; MALE; TIME; TREATMENT OUTCOME;

ANIMALS; ANTICONVULSANTS; BROMIDES; DOG DISEASES; DOGS; EPILEPSY; FEMALE; MALE; PHENOBARBITAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 84859965730     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: 10.2460/javma.240.9.1073     Document Type: Article

References (50)

1. Parent JM. Clinical management of canine seizures. Vet Clin North Am Small Anim Pract 1988;18:947-965.
2. Lane SB, Bunch SE. Medical management of recurrent seizures in dogs and cats. J Vet Intern Med 1990;4:26-39.
3. Pearce LK. Potassium bromide as an adjunct to phenobarbital for the management of uncontrolled seizures in dogs. Prog Vet Neurol 1990;1:195-101.
4. Podell M, Fenner WR. Bromide therapy in refractory canine idiopathic epilepsy. J Vet Intern Med 1993;7:318-327.
5. Podell M. Seizures in dogs. Vet Clin North Am Small Anim Pract 1996;26:779-809.
6. Trepanier LA. Use of bromide as an anticonvulsant for dogs with epilepsy. J Am Vet Med Assoc 1995;207:163-166.
7. Boothe DM. Anticonvulsant and other neurologic therapies. In: Boothe DM, ed. Small animal clinical pharmacology and therapeutics. Philadelphia: WB Saunders Co, 2001;431-456.
8. Dewey CW. Anticonvulsant therapy in dogs and cats. Vet Clin North Am Small Anim Pract 2006;36:1107-1127.
9. Pedersoli WM, Wike JS, Ravis WR. Pharmacokinetics of single doses of phenobarbital given intravenously and orally to dogs. Am J Vet Res 1987;48:679-683.
10. Ravis WR, Pedersoli WM, Wike JS. Pharmacokinetics of phenobarbital in dogs given multiple doses. Am J Vet Res 1989;50:1343-1347.
11. Trepanier LA, Babish JG. Pharmacokinetic properties of bromide in dogs after the intravenous and oral administration of single doses. Res Vet Sci 1995;58:248-251.
12. Cunningham JG, Haidukewych D, Jensen HA. Therapeutic serum concentrations of primidone and its metabolites, phenobarbital and pheynlethylmalonamide in epileptic dogs. J Am Vet Med Assoc 1983;182:1091-1094.
13. Morton DJ, Honhold N. Effectiveness of a therapeutic drug monitoring service as an aid to the control of canine seizures. Vet Rec 1988;122:346-349.
14. Levitski RE, Trepanier LA. Effect of timing of blood collection on serum phenobarbital concentrations in dogs with epilepsy. J Am Vet Med Assoc 2000;217:200-204.
15. Grewal MS, Swinyard EA, Jensen HV, et al. Correlation between anticonvulsant activity and plasma concentration of bromide. J Pharmacol Exp Ther 1954;112:109-115.
16. Trepanier LA, Van Schoick A, Schwark WS, et al. Therapeutic serum drug concentrations in epileptic dogs treated with potassium bromide alone or in combination with other anticonvulsants: 122 cases (1992-1996). J Vet Intern Med 1998;213:1449-1453.
17. US Pharmacopeia. Bromide compounding monograph. In: United States pharmacists' pharmacopeia 2008-2009. Rockville, Md: US Pharmacopeial Convention, 2009.
18. Dayrell-Hart B, Steinberg SA, VanWinkle TJ, et al. Hepatotoxicity of phenobarbital in dogs: 18 cases (1985-1989). J Am Vet Med Assoc 1991;199:1060-1066.
19. Gaskill CL, Miller LM, Mattoon JS, et al. Liver histopathology and liver and serum alanine aminotransferase and alkaline phosphatase activities in epileptic dogs receiving phenobarbital. Vet Pathol 2005;42:147-160.
20. Muller PB, Taboada J, Hosgood G, et al. Effects of long-term phenobarbital treatment on the liver in dogs. J Vet Intern Med 2000;15:165-171.
21. Jacobs G, Calvert C, Kaufman A. Neutropenia and thrombocytopenia in three dogs treated with anticonvulsants. J Am Vet Med Assoc 1998;212:681-684.
22. Stokol T, Blue JT, French TW. Idiopathic pure red cell aplasia and nonregenerative immune-mediated anemia in dogs: 43 cases (1988-1999). J Am Vet Med Assoc 2000;216:1429-1436.
23. Aldridge A, Neims AH. The effects of phenobarbital and 2-naphthoflavone on the elimination kinetics and metabolite pattern of caffeine in the Beagle dog. Drug Metab Dis 1979;7:378-382.
24. Bekersky I, Maggio AC, Mattaliano V Jr, et al. Influence of phenobarbital on the disposition of clonazepam and antipyrine in the dog. J Pharmacokinet Biopharm 1977;5:507-512.
25. Sams RA, Muir WW. Effects of phenobarbital on thiopental pharmacokinetics in Greyhounds. Am J Vet Res 1988;49:245-249.
26. Ciaccio PJ, Halpert JR. Characterization of a phenobarbitalinducible dog liver cytochrome P450 structurally related to rat and human enzymes of the P450IIIA (steroid-inducible) gene subfamily. Arch Biochem Biophys 1989;271:284-299.
27. Nossaman BC, Amouzadeh HR, Sangiah S. Effects of chloramphenicol, cimetidine and phenobarbital on and tolerance to xylazineketamine anesthesia in dogs. Vet Hum Toxicol 1990;32:216-219.
28. Kantrowitz LB, Peterson ME, Trepanier LA, et al. Serum total thyroxine, total triiodothyronine, free thyroxine, and thyrotropin concentrations in epileptic dogs treated with anticonvulsants. J Am Vet Med Assoc 1999;214:1804-1808.
29. Hojo T, Ohno R, Shimoda M, et al. Enzyme and plasma protein induction by multiple oral administrations of phenobarbital at a therapeutic dosage regimen in dogs. J Vet Pharmacol Ther 2002;25:121-127.
30. Orito K, Saito M, Fukunaga K, et al. Pharmacokinetics of zonisamide and drug interaction with phenobarbital in dogs. J Vet Pharmacol Ther 2008;31:259-264.
31. Gieger TL, Hosgood G, Taboada J, et al. Thyroid function and serum hepatic enzyme activity in dogs after phenobarbital administration. J Vet Intern Med 2000;14:277-281.
32. Muller PB, Wolfsheimer KJ, Taboada J, et al. Effects of long-term phenobarbital treatment on the thyroid and adrenal axis and adrenal function tests in dogs. J Vet Intern Med 2000;15:157-164.
33. Trepanier LA, Babish JG. Effect of dietary chloride content on the elimination of bromide by dogs. Res Vet Sci 1995;58:252-255.
34. Shaw N, Trepanier LA, Center SA, et al. High dietary chloride content associated with loss of therapeutic serum bromide concentrations in an epileptic dog. J Am Vet Med Assoc 1996;208:234-236.
35. Nichols ES, Trepanier LA, Linn K. Bromide toxicosis secondary to renal insufficiency in an epileptic dog. J Am Vet Med Assoc 1996;208:231-233.
36. Rossmeisl JH, Inzana KD. Clinical signs, risk factors, and outcomes associated with bromide toxicosis (bromism) in dogs with idiopathic epilepsy. J Am Vet Med Assoc 2009;234:1425-1431.
37. Extralabel drug use in animals; final rule, 21 CFR Part 530. Fed Regist 1996;61:57731-57746.
38. US FDA Center for Veterinary Medicine. Chapter 6, Subchapter 600, Sec. 608.400-compounding of drugs for use in animals, July 2003. In: Compliance policy guide: compliance policy guidance for FDA staff and industry. Rockville, Md: US FDA, 2003. Available at: www.fda.gov/ICECI/ComplianceManuals/CompliancePolicyGuidanceManual/ucm074656. htm. Accessed Mar 27, 2012.
39. Boothe DM. Therapeutic drug monitoring. In: Boothe DM, ed. Small animal clinical pharmacology and therapeutics. Philadelphia: WB Saunders Co, 2001;60-72.
40. Bauer LH. Handbook of clinical pharmacokinetics. Columbus, Ohio: McGraw-Hill, 2005.
41. US FDA Good Clinical Practice Program Office of Science & Health Coordination, Office of the Commissioner. Guidance for sponsors, clinical investigators, and IRBs: data retention when subjects withdraw from FDA-regulated clinical trials. HF-34. Available at: www.fda.gov/oc/gcp/draft.html. Accessed Jun 22, 2010.
42. Loomis KF, Frye RM. Evaluation of the Abbott TDx for the stat measurement of phenobarbital, phenytoin, carbamazepine, and theophylline. Am J Clin Pathol 1983;80:686-691.
43. Sunshine I. Bromide. Type A. Procedure. In: Sunshine I, ed. CRC methodology for analytical toxicology. Cleveland: CRC Press, 1975;54-55.
44. US Pharmacopeia (USP-NF). USP33-NF28. Potassium bromide oral solution monograph. In: The United States pharmacopeia. Rockville, Md: US Pharmacopeial Convention, 2010;3:4375.
45. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006;354:731-739.
46. Lam FC, Hung CT, Perrier DG. Estimation of variance for harmonic mean half-lives. J Pharm Sci 1985;74:229-231.
47. Sazgar M, Bourgeois BF. Aggravation of epilepsy by antiepileptic drugs. Pediatr Neurol 2005;33:227-234.
48. Kluger EK, Malik R, Ilkin WJ, et al. Serum triglyceride concentration in dogs with epilepsy treated with phenobarbital or with phenobarbital and bromide. J Am Vet Med Assoc 2008;233:1270-1277.
49. Gaskill CL, Cribb AE. Pancreatitis associated with potassium bromide/phenobarbital combination therapy in epileptic dogs. Can Vet J 2000;41:555-558.
50. Steiner JM, Xenoulis PG, Anderson JA, et al. Serum pancreatic lipase immunoreactivity concentrations in dogs treated with potassium bromide and/or phenobarbital. Vet Ther 2008;9:37-44.